MasterBrand's rating was lowered from 'Strong Buy' to 'Buy' due to a decline in profitability and challenges in the housing market. The company's EBITDA margin dropped from 12.2% to 7.2%, with a trailing 12-month EBITDA of $294.5 million, reflecting weaker revenue and consumer spending shifts. Synergy targets from its merger with American Woodmark have increased to $100 million, with half expected in the first year. Despite high net leverage, the stock remains attractively priced, and management aims to reduce leverage below 2 by 2028.
MasterBrand's recent downgrade is presented here with Pluang's Consumer Cyclical sector data as of Sep 18, 2026 13:21 WIB. For readers following this sector, 62 out of 105 priced US stocks rose while 40 fell. Notable movers include Victoria's Secret & Co (VSXY) at USD 76.90 with a 3.98% increase and a Pluang order activity of 92% Buy, Burlington Stores Inc (BURL) at USD 239.66 up 3.88% with 100% Buy activity, and Alibaba Group (BABA) at USD 112.72 rising 3.86% but with 59% Sell activity. The most notable figure is Burlington Stores Inc's 100% Buy order activity on Pluang.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
